North Carolina Headlines

retinal pigment epithelium market report DelveInsight

DelveInsight’s report, “Pigment Epithelial Detachment – Market Insight, Epidemiology and Market Forecast”, provides a comprehensive assessment of retinal pigment epithelium market dynamics, disease epidemiology, and treatment advancements across the 7MM. The report forecasts that the retinal pigment epithelium market size in these regions, which include the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase significantly in the coming years. This growth will be largely due to an aging population, industry collaborations, and advancements in technologies such as AI-driven diagnostics, telehealth, and therapeutic innovations.

The US currently holds the largest retinal pigment epithelium market share, a trend anticipated to continue due to ongoing innovations in anti-VEGF therapies and advancements in the treatment pipeline. Moreover, Japan’s growth rate could surpass others, owing to its aging population and a higher prevalence of PCV-related PED.

Download the Pigment Epithelial Detachment Market report to understand which factors are driving the retinal pigment epithelium therapeutic market @ Pigment Epithelial Detachment Market Trends.

The epidemiological data presented in the report indicate key trends in incidence, demographics, and the retinal pigment epithelium patient pool. Pigment epithelial detachment is a significant retinal disorder, often associated with age-related macular degeneration (AMD), central serous chorioretinopathy (CSCR), and other retinal diseases, leading to a marked increase in prevalence among the elderly. The average age of patients with drusenoid retinal pigment epithelium is 77 years.

Discover evolving trends in the retinal pigment epithelium patient pool forecasts @ Pigment Epithelial Detachment Epidemiology Analysis.

The report also examines the current and evolving retinal pigment epithelium treatment landscape. Intravitreal anti-VEGF agents, like AVASTIN (Roche), Ranibizumab, and Aflibercept, remain the cornerstone for treating vascularized PEDs associated with neovascular AMD. Combination therapies, particularly those that involve anti-VEGF agents alongside photodynamic therapy, such as, have shown promise for managing large or treatment-resistant pigment epithelial detachments.

ONL-1204, developed by ONL Therapeutics, is a novel, first-in-class small-molecule peptide currently in Phase II clinical trials for the treatment of pigment epithelial detachment. ONL-1204 works by inhibiting the Fas receptor to protect retinal cells and photoreceptors from apoptosis and preserve vision. In Phase I and II studies, ONL-1204 has demonstrated encouraging results, showing visual benefits, especially in patients at high risk of vision loss. The ongoing Phase II trial is evaluating two dosing regimens and will provide critical data to support further development towards pivotal Phase III studies.

Looking ahead, the pigment epithelial detachment treatment landscape is rapidly advancing, with significant progress in cell and gene therapy for retinal diseases, especially AMD. Research continues to refine techniques for retinal pigment epithelium transplantation, focusing on the development of new scaffolds and delivery methods to ensure proper oxygenation and cell adhesion for both RPE and outer retina cells.

Moreover, advancements in retinal imaging, such as Laser Doppler holography, are enhancing the visualization of blood flow and other retinal structures, which could improve diagnostics and treatment planning. In late 2024, machine learning algorithms for the automated detection of PEDs from optical coherence tomography images have shown promising results, with logistic regression models achieving over 96% accuracy.

In November 2025, LumiThera received FDA authorization to market its Valeda Light Delivery System, which is the first therapy utilizing photobiomodulation (PBM) to improve visual acuity in patients with intermediate AMD. This approval is based on data from the LIGHTSITE III trial (NCT04065490), which showed durable best-corrected visual acuity improvements of more than five letters maintained over 24 months. Additionally, research published in December 2024 highlighted the role of fatty acid desaturase 1 (FADS1) in RPE ferroptosis and AMD progression, identifying FADS1 inhibition as a potential therapeutic target, reflecting the active pace of development and market growth potential in PED treatments.

Unlock which retinal pigment epithelium emerging drug is expected to capture the largest market share in 7MM by 2032. Visit the Pigment Epithelial Detachment Drug Insights.

In conclusion, despite facing challenges such as immune rejection in allogeneic transplants, surgical complications, high production costs, and limited accessibility, the retinal pigment epithelium market is on a strong growth trajectory, fueled by an aging population, innovative therapeutic strategies, and rapid technological advancements in diagnostics and imaging.

With promising developments in anti-VEGF agents, photobiomodulation therapies, and emerging gene and cell therapies, the treatment approach for PED is shifting towards more targeted, effective, and personalized care. As leading players continue to invest in research, collaboration, and innovative pipelines, the PED market is well-positioned for substantial transformation.

Table of Contents

Related Reports

Age-Related Macular Degeneration (AMD) Pipeline Insight

Age-Related Macular Degeneration Pipeline Insight provides comprehensive insights about the AMD pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the age-related macular degeneration companies, including Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics and Novartis, Luxa Biotechnology, and Gemini Therapeutics, among others.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services